Cognition Therapeutics (CGTX) Total Non-Current Liabilities (2020 - 2024)
Cognition Therapeutics (CGTX) posted quarterly Total Non-Current Liabilities of $13.1 million for Q3 2024, up 33.02% year-over-year from $9.8 million in Q4 2023, and up 15.29% quarter-over-quarter from $11.4 million in Q2 2024.
Cognition Therapeutics (CGTX) Total Non-Current Liabilities (2020 - 2024) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Total Non-Current Liabilities for 5 consecutive years, with $13.1 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Total Non-Current Liabilities rose 33.02% year-over-year to $13.1 million; the TTM figure through Sep 2024 stood at $13.1 million (up 33.02% YoY), while the FY2023 annual figure was $10.7 million, up 25.9% from the prior year.
- Total Non-Current Liabilities rose to $13.1 million in Q3 2024 per CGTX's latest filing, from $11.4 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $17.7 million in Q4 2020 and bottomed at $7.2 million in Q2 2022.
- Historically, Total Non-Current Liabilities has averaged $10.3 million across 5 years, with a median of $9.8 million in 2023.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities sank 55.63% — and 2024, when it surged 33.3%.
- Cognition Therapeutics' Total Non-Current Liabilities stood at $17.7 million in 2020, then tumbled by 55.63% to $7.9 million in 2021, then advanced by 7.96% to $8.5 million in 2022, then climbed by 25.9% to $10.7 million in 2023, then advanced by 22.53% to $13.1 million in 2024.
- Business Quant data shows CGTX's Total Non-Current Liabilities at $13.1 million in Q3 2024, $11.4 million in Q2 2024, and $10.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 13.10 Mn |
| Jun 30, 2024 | 11.36 Mn |
| Mar 31, 2024 | 9.99 Mn |
| Dec 31, 2023 | 10.69 Mn |
| Sep 30, 2023 | 9.85 Mn |
| Jun 30, 2023 | 8.52 Mn |
| Mar 31, 2023 | 8.12 Mn |
| Dec 31, 2022 | 8.49 Mn |
| Sep 30, 2022 | 12.72 Mn |
| Jun 30, 2022 | 7.22 Mn |
| Mar 31, 2022 | 8.09 Mn |
| Dec 31, 2021 | 7.86 Mn |
| Dec 31, 2020 | 17.72 Mn |